Meet Ottava, J&J’s surgical robot leading the healthcare giant into a lucrative new market
Johnson & Johnson is diving head-first into the deep end of the competitive robotic surgery market. The payoff…
Johnson & Johnson Stock Jumps 3% as Healthcare Rotation Lifts Shares
This article first appeared on GuruFocus. Johnson & Johnson (NYSE:JNJ), the healthcare heavyweight behind blockbuster medicines and medical…
Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7%…
We’re lifting our price target on Cardinal Health after issuing rosy profit guidance
Cardinal Health on Tuesday showed why the healthcare distributor belongs in our portfolio, delivering robust full-year earnings guidance…
Johnson & Johnson baby powder lawsuit: J&J offers $5.5 billion to settle 76,000 cancer claims
Johnson & Johnson (J&J) has agreed to pay an estimated $5.5 billion to settle tens of thousands of…
How a 44-Year-Old Could Build a $9,000 Monthly Paycheck by 60 Without Maxing a 401(k)
Quick Read Generating $108,000 annually from dividends requires roughly $2.7M at a 4% yield, $1.8M at 6%, or…
Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7%…
Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories
Quick Read JNJ’s 64-year dividend streak and oncology momentum make it the steadier buy, while ABT’s 18x forward…
Market for psychedelic drugs to treat mental health gets a buy signal
Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement…
We’re trimming a stock into strength, raising our price target
We are selling 50 shares of Cardinal Health at roughly $235. Following the trade, Jim Cramer’s Charitable Trust…
Johnson & Johnson CEO: America’s innovation advantage starts with health
Johnson & Johnson CEO: America’s innovation advantage starts with health | Fortune Joaquin Duato is Chairman and Chief…
J&J starts head-to-head PFA trial against Boston Scientific device
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free…